aibioMetaVia to present Phase 1 DA-1726 data at Precision Liver Symposium
Tickers MTVA
An abstract on the Phase 1 trial of DA-1726 was accepted for an oral presentation at the Precision Liver Symposium 2026 in Denver on November 4, 2026.
Key facts
- Company
- MetaVia Inc. (NASDAQ: MTVA)
- News type
- Company Updates
- Primary source
- MetaVia Inc. 8-K (2026-10-28)
MetaVia Inc. (Nasdaq: MTVA) said on October 28, 2026 that an abstract highlighting Phase 1 clinical trial data for DA-1726 has been accepted for an oral presentation at the Precision Liver Symposium 2026. The symposium takes place November 4, 2026, in Denver, Colorado. DA-1726 is a novel oxyntomodulin analogue that acts as a dual agonist of the GLP-1 and glucagon receptors, and the company is developing it for the treatment of metabolic disease. The release gives the abstract's title as "DA-1726, a Dual GLP-1 and Glucagon Receptor Agonist, Leads to Significant Reduction in MRI-PDFF and Weight Loss with Relative Preservation of Lean Mass: A Randomized Placebo-Controlled Trial."
The presentation
The presenting author is Sarah Browne, M.D., the company's Chief Medical Officer. The presentation is scheduled for 1:35 pm MT at the Hilton Denver City Center. The company says a copy of the poster will be available in the Posters section of its website after the presentation.
According to the release, the abstract covers a randomized, placebo-controlled trial in which DA-1726 led to a significant reduction in MRI-PDFF and in weight, with relative preservation of lean mass. The release does not give the trial's numbers, and the results will be shown at the symposium.
The release is dated from Cambridge, Massachusetts. It lists Marshall H. Woodworth, Chief Financial Officer, as the company's contact, and Rx Communications Group as the media contact.
About DA-1726
The release says DA-1726 is designed to be administered once weekly under the skin. It acts on GLP-1 receptors, which reduce appetite, and on glucagon receptors, which increase energy expenditure. In preclinical mouse models, the company says DA-1726 produced improved weight loss compared with semaglutide, a leading GLP-1 receptor agonist.
The release also says that in the Phase 1 multiple ascending dose trial in obesity, the 32 mg dose of DA-1726 demonstrated best-in-class potential for weight loss, glucose control and waist circumference reduction. These are the company's own descriptions of the data. The release adds that in preclinical mouse models DA-1726 elicited similar weight reduction to tirzepatide and survodutide while the animals consumed more food, preserved lean body mass, and showed improved lipid-lowering effects compared with survodutide. It also says the Phase 1 multiple ascending dose trial showed encouraging liver-related findings, including improvements in noninvasive measures of hepatic steatosis and liver stiffness.
The company and its financial position
The release describes the company as developing DA-1726 for treatment across multiple cardiometabolic indications, and vanoglipel (DA-1241) for MASH.
MetaVia's annual report, filed March 26, 2026, describes two programs. One is vanoglipel (DA-1241), a GPR119 agonist for MASH and Type 2 diabetes. The other is DA-1726 for obesity. The report says the company started the Phase 1 trial of DA-1726 in 2024. It also describes four legacy therapeutic programs that MetaVia is not planning to advance and may out-license or divest.
The annual report shows research and development expense of $6.8 million for the year ended December 31, 2025, compared with $21.6 million for 2024. Net loss was $13.0 million for 2025 and $27.6 million for 2024. Cash used in operations was $15.7 million in 2025 and $24.7 million in 2024. A quarterly report filed August 6, 2026 shows cash and cash equivalents of $12.6 million at June 30, 2026.
What the release leaves out
The release gives no numbers for the abstract's claim of a significant reduction in MRI-PDFF and weight loss, and no safety data, so the title is all that can be checked until November 4. The comparisons with semaglutide, tirzepatide and survodutide are from mouse models, not people, and "best-in-class potential" is the company's phrase. The annual report says the Part 3a and Part 3b titration studies are meant to remove moderate adverse effects at the 48 mg dose and to test a higher 64 mg dose, with both readouts planned for the fourth quarter of 2026. Part 3a tests 16 mg for four weeks and then 48 mg for 12 weeks.
Cash of $12.6 million at June 30, 2026 compares with cash used in operations of $15.7 million in 2025. The release lists the company's history of net losses and the sufficiency of its cash among its risks.